Eli Lilly and Company, a leading pharmaceutical group, is expected to see an increase in Zepbound sales in Q1, according to UBS. The company's sales are primarily driven by endocrinology (65.5%), followed by oncology (19.4%), immune diseases (9.8%), neurology (3.3%), and other areas (2%). Geographically, 67.4% of sales come from the United States, with Europe at 15.4%, Japan at 4%, China at 3.7%, and other regions at 9.5%.